Xultophy and Soliqua Will Be the First Basal Insulin/GLP-1 Agonist Combos

October 2018

Xultophy (ZUL-toh-fye) and Soliqua (soh-LEE-kwa) will be two new once-daily injectables for type 2 diabetes.

These meds are the first basal insulin/GLP-1 agonist combos.

Xultophy combines insulin degludec (Tresiba) and liraglutide (Victoza) into a single injection...and Soliqua combines insulin glargine (Lantus, etc) plus lixisenatide (Adlyxine).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Influenza Sort Through Influenza Vaccine Options for 2018-19
Diabetes Xultophy and Soliqua Will Be the First Basal Insulin/GLP-1 Agonist Combos
Epinephrine Clear Up Confusion About EpiPen Shortages and Auvi-Q
Migraine Prevent Mishaps With the New, Injectable Aimovig for Migraine Prevention
Practice Remember "Cooler Heads Prevail" When Conflict Arises
Dermatology Know How Diaper Rash Remedies Stack Up
Pharmacogenetics Keep the Role of Pharmacogenetic Testing for Mental Health Meds in Perspective
Natural Medicines Focus on Safety if Patients Use Essential Oils
HIV & AIDS Expect to See More HIV Meds Containing "Integrase Inhibitors"

Xultophy and Soliqua Will Be the First Basal Insulin/GLP-1 Agonist Combos

Practical advice for a better career, with unlimited access to CE

Table of Contents